CTRI/2021/09/036317已完成2 期
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 163
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Willing and able to provide informed consent.
- •2.Males and females of = 18 years of age, at the time of signing the informed consent.
- •3.Patient with mild COVID-19 infection having = 1 symptoms. Mild infection is defined as presence of any one of the signs and symptoms of COVID-19 such as fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and/or smell, without shortness of breath or hypoxia. The respiratory rate should be < 24/min and SpO2 = 94% on room air. Patients should have one or more of these symptoms on the day of start of treatment.
- •4.Laboratory confirmed Covid-19 infection by Reverse Transcription Polymerase Chain Reaction (RT-PCR) in nasopharyngeal sample (within 72 hours prior to randomization).
- •5. Patient should have at least one pre-existing high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity (Body mass index (BMI) > 30.0 kg/m2), cancer) for developing severe Covid-19 illness.
- •6. Ability to swallow and retain oral medication.
- •7. Male patient who is surgically sterile, or who is willing to agree to remain completely abstinent or will agree to use barrier contraceptive measures and agrees to refrain from donating sperm during the entire study treatment period and for 3 months after the last dose of study drug.
- •8. Women of childbearing potential who should be willing to use a medically acceptable method of contraception as defined in Appendix B while participating in the study and for 30 days after the last dose of study drug AND must have a negative pregnancy test within 3 days prior to dosing on Day 1.
- •9. Willing to receive telephone calls or have videoconferences with study
- •team personnel.
- •10. Willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.
排除标准
- •Individuals who meet any of the following criteria will be considered ineligible to participate in the study:
- •1. Patient with asymptomatic Covid-19 infection.
- •2. Patient who has experienced onset of any of Covid-19 symptoms > 5 days at the time of randomization.
- •3. Moderate to Severe COVID-19 infection.
- •-Moderate infection is defined as patients with pneumonia with no signs of severe disease. Clinical features suggestive of presence of dyspnea and/or hypoxia, fever, cough, including SpO2 = 93% (range 90-93%) on room air OR respiratory rate = 24 per minute.
- •-Severe infection is defined as patients with either severe pneumonia, acute respiratory distress syndrome, sepsis or septic shock. Clinical features suggestive of clinical signs of pneumonia plus one of the following parameters such as respiratory rate > 30 breaths/min, severe respiratory distress and SpO2 < 90% on room air; or signs of acute respiratory distress syndrome or sepsis or septic shock.
- •4. Subjects who are severely immunocompromised (e.g., subjects with HIV infection, subjects with solid organ transplantation or bone marrow transplantation, subjects receiving chemotherapy/ radiotherapy, subjects with primary immunodeficiency).
- •5. Autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA).
- •6. Patients with any bleeding disorder e.g., hemophilia and von Willebrand disease.
- •7. Current use of other DHODH inhibitors including teriflunomide or leflunomide.
- •8. Patients who are on or immediately require Covid-19 directed treatment such as antivirals (e.g., remdesivir, favipiravir), immunomodulatory treatment (e.g., tocilizumab, itolizumab, baricitinib or JAK inhibitors), convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening.
- •9. Patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing.
- •10. Patient with history of heart failure, Class 2 or greater using the New York Heart Association (NYHA) functional class.
- •11. Patients on medication that is associated with prolonged QT such as antipsychotic medications or antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop the same during the trial.
- •12. Pregnant or lactating females.
- •13. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient.
- •14. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
- •15. Concurrent condition that in the investigator’s opinion would jeopardize compliance with the protocol.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
不适用
A Clinical Trial Investigating OSI-906 in Patients with Adrenocortical CarcinomaAdrenocortical CarcinomaMedDRA version: 14.1Level: PTClassification code 10001388Term: Adrenocortical carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012820-97-DEAstellas Pharma Global Development, Inc.135
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast carcinoma10006291Breast cancerNL-OMON51870Merck Sharp & Dohme (MSD)24
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282